Reparixin in COVID-19 Pneumonia - Efficacy and Safety

NCT04794803 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
56
Enrollment
INDUSTRY
Sponsor class

Stopped The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.

Conditions

Interventions

Sponsor

Dompé Farmaceutici S.p.A